Orris

Myasthenia gravis

Reading File
Finding Sources
Searching PubMed

"myasthenia gravis" AND treatment

Myasthenia gravis (MG) is a broad topic spanning pathophysiology, clinical presentation, diagnosis, and management. Here's the landscape based on the medical library (primarily Bradley and Daroff's Neurology in Clinical Practice, plus family medicine, ENT, cardiology, and emergency medicine texts) and recent literature:

Topic Breakdown

  1. Pathophysiology & Immunology - autoimmune attack on the neuromuscular junction (anti-AChR antibodies, anti-MuSK, anti-LRP4), thymus involvement
  2. Clinical Presentation - ocular (ptosis, diplopia), bulbar (dysarthria, dysphagia), limb weakness, fatigability pattern, myasthenic crisis
  3. Diagnosis - antibody testing, repetitive nerve stimulation, single-fiber EMG, edrophonium (Tensilon) test, imaging for thymoma
  4. Treatment - symptomatic (pyridostigmine), immunosuppression (steroids, azathioprine, mycophenolate), biologics (rituximab, eculizumab, efgartigimod), IVIG/plasmapheresis, thymectomy
  5. Myasthenic Crisis & Emergency Management - respiratory failure, triggers, ICU care
  6. Special Situations - drug-induced exacerbations, pregnancy, anesthesia considerations, MG in surgical/ENT context

Brief Overview

MG is an autoimmune disorder of the neuromuscular junction, most commonly caused by antibodies against the postsynaptic acetylcholine receptor (AChR), which reduce the number of functional receptors and impair neuromuscular transmission - producing the hallmark feature of fatigable weakness that worsens with exertion and improves with rest. A minority of patients have antibodies against muscle-specific kinase (MuSK) or LRP4 instead. The thymus is often abnormal (hyperplasia or thymoma) and plays a role in disease pathogenesis.
Clinically, ocular symptoms (ptosis, diplopia) are the most common initial presentation, and disease can remain localized or generalize to bulbar and limb muscles. The most feared complication is myasthenic crisis - respiratory muscle weakness requiring ventilatory support.
Diagnosis relies on antibody testing (AChR-binding/blocking/modulating antibodies, anti-MuSK), electrodiagnostic studies (repetitive nerve stimulation, single-fiber EMG showing increased jitter), and sometimes the edrophonium test. Treatment is tiered: pyridostigmine for symptom control, corticosteroids and steroid-sparing immunosuppressants for disease control, and newer targeted biologics (complement inhibitors like eculizumab/ravulizumab, FcRn inhibitors like efgartigimod, and rituximab) for refractory or antibody-specific subtypes. Thymectomy is recommended for thymoma and considered in AChR-antibody-positive generalized MG. IVIG and plasma exchange are used for crisis or rapid pre-surgical optimization.
Recent evidence: a 2025 network meta-analysis (PMID 40346603) compared novel biologics (efgartigimod, rozanolixizumab, eculizumab, etc.) for efficacy and acceptability in MG treatment - relevant if you want current comparative data on newer agents rather than older textbook coverage.
Which topic would you like me to go into in detail?
Asking for Preferences

Which aspect of myasthenia gravis would you like a detailed deep-dive on?

This is a shared conversation. Sign in to Orris to start your own chat.